Skip to main content
. 2016 Jun 22;82(3):839–848. doi: 10.1111/bcp.13019

Table 3.

Adjusted odds ratios (aOR) and 95% confidence intervals (CI) for venous thromboembolism in subcohorts (numbers in bold indicate significant results)

Cases n (%) Controls n (%) aOR (95% CI)#
Excluding CKD patients *, 2755 (100) 22 983 (100)
Epoetins 71 (2.6) 549 (2.4) 1.38 (1.04, 1.84)
Transfusions 962 (34.9) 6483 (28.2) 2.46 (2.11, 2.86)
Epoetins and transfusions 19 (0.7) 79 (0.3) 2.46 (1.40, 4.34)
Only patients additionally suffering from CKD *, 556 (100) 5214 (100
Epoetins 25 (4.5) 266 (5.1) 1.56 (0.84, 2.90)
Transfusions 203 (36.5) 1439 (27.6) 1.74 (1.06, 2.86)
Epoetins and transfusions 3 (0.5) 16 (0.3) 1.72 (0.17, 17.67)
Only patients with lung cancer **, 333 (100) 1511 (100)
Epoetins 9 (2.7) 39 (2.6) 1.65 (0.72, 3.76)
Transfusions 157 (47.2) 644 (42.6) 1.84 (1.21, 2.80)
Epoetins and transfusions 5 (1.5) 12 (0.8) 3.80 (1.08, 13.42)
Only patients with lung or pancreatic cancer **, 571 (100) 2685 (100)
Epoetins 16 (2.8) 83 (3.1) 1.33 (0.74, 2.41)
Transfusions 266 (46.6) 1126 (41.9) 1.85 (1.34, 2.56)
Epoetins and transfusions 6 (1.1) 16 (0.6) 2.47 (0.86, 7.06)
Only patients with prostate or breast cancer **, 411 (100) 1976 (100)
Epoetins 24 (5.8) 113 (5.7) 1.05 (0.59, 1.88)
Transfusions 139 (33.8) 540 (27.3) 2.60 (1.58, 4.28)
Epoetins and transfusions 2 (0.5) 11 (0.6) 0.67 (0.11, 4.06)
Start of anaemia treatment until June 2008 *, 2500 (100) 19 402 (100)
Epoetins 78 (3.1) 522 (2.7) 1.33 (1.02, 1.72)
Transfusions 773 (30.9) 4229 (21.8) 2.34 (1.99, 2.76)
Epoetins and transfusions 15 (0.6) 52 (0.3) 2.34 (1.23, 4.45)
Start of anaemia treatment after June 2008 *, 780 (100) 2280 (100)
Epoetins 16 (2.1) 56 (2.5) 0.83 (0.40, 1.75)
Transfusions 380 (48.7) 1025 (45.0) 2.52 (1.76, 3.60)
Epoetins and transfusions 7 (0.9) 10 (0.4) 1.52 (0.47, 4.89)
*

Matching was performed for age, gender and SHI.

**

Matching was performed for age, gender, SHI and metastatic disease.

#

It was adjusted for history of VTE, obesity, metastatic solid tumour, surgery, chemotherapy, other medication associated with increased VTE risk (Table S3), antithrombotic medication (Table S4) coronary artery disease/chronic ischemic heart disease, arterial hypertension, dyslipidaemia, diabetes mellitus, myocardial infarction and angina pectoris.

Reference group: past users of epoetin and/or transfusion.

Past treatment with epoetin and/or transfusion means that the last dispensation of epoetin or administration of transfusion was longer than 28 days before the index date.

CKD chronic kidney disease; SHI statutory health insurance.